Group 3F: Breast Cancer; HER2+; Antibody-Drug Conjugates; Cardiotoxicity; Interstitial Lung Disease

Poster #P1-02-08: Incidence of cardiotoxicity in patients with breast cancer receiving human epidermal growth factor 2 (HER2) targeted monoclonal antibodies and antibody-drug conjugates: A Systematic review and meta-analysis

Poster #P1-02-10: Real World Analysis of interstitial Lung Disease in Patients with HER2-Positive unresectable or recurrent Breast Cancer Treatment with Trastuzumab Deruxtecan: An all Patient Post-Marketing surveillance Study in Japan